Nephropathy Clinical Trials

129 recruitingLast updated: June 18, 2026

There are 129 actively recruiting nephropathy clinical trials across 54 countries. Studies span Phase 2, Not Applicable, Phase 3, Phase 1, Phase 4, Early Phase 1. Top locations include Houston, Texas, United States, Beijing, Beijing Municipality, China, Beijing, China. Updated daily from ClinicalTrials.gov.


Nephropathy Trials at a Glance

129 actively recruiting trials for nephropathy are listed on ClinicalTrialsFinder across 6 cities in 54 countries. The largest study group is Phase 2 with 35 trials, with the heaviest enrollment activity in Houston, Beijing, and Beijing. Lead sponsors running nephropathy studies include Novartis Pharmaceuticals, The Children's Hospital of Zhejiang University School of Medicine, and Alexion Pharmaceuticals, Inc..

Browse nephropathy trials by phase

Treatments under study

About Nephropathy Clinical Trials

Looking for clinical trials for Nephropathy? There are currently 8 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Nephropathy trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Nephropathy clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 129 trials

Recruiting
Phase 3

A Study to Learn About the Effects of Felzartamab Infusions on Adults With Immunoglobulin A Nephropathy (IgAN)

Immunoglobulin A Nephropathy (IgAN)
Biogen454 enrolled244 locationsNCT06935357
Recruiting
Not Applicable

Immunopathological Analysis in a French National Cohort of Membranous Nephropathy

Membranous Nephropathy
Centre Hospitalier Universitaire de Nice400 enrolled1 locationNCT04326218
Recruiting
Phase 2

Phase 2 Study of ADX-038 in Complement-Mediated Kidney Disease

IgA Nephropathy (IgAN)IgANC3G+2 more
ADARx Pharmaceuticals, Inc.45 enrolled29 locationsNCT06989359
Recruiting
Phase 2

Chinese Adults With Kidney Disease

Immunoglobulin A Nephropathy (IgAN)IC-MPGNComplement 3 Glomerulopathy (C3G)
ADARx Pharmaceuticals, Inc.30 enrolled10 locationsNCT07522099
Recruiting
Phase 3

A Study to Evaluate the Efficacy and Safety of Sefaxersen (RO7434656) in Participants With Primary Immunoglobulin A (IgA) Nephropathy at High Risk of Progression

Primary IgA Nephropathy
Hoffmann-La Roche428 enrolled204 locationsNCT05797610
Recruiting
Phase 3

A Study to Learn More About the Effects and Safety of Felzartamab Infusions in Adults With Primary Membranous Nephropathy (PMN)

Primary Membranous Nephropathy
Biogen180 enrolled102 locationsNCT06962800
Recruiting

Nephrotic Syndrome Study Network

Membranous NephropathyGlomerulosclerosis, Focal SegmentalMinimal Change Disease (MCD)
University of Michigan1,200 enrolled44 locationsNCT01209000
Recruiting
Not Applicable

NEPTUNE Match Study

Nephrotic Syndrome in ChildrenAlport SyndromeFocal Segmental Glomerulosclerosis+6 more
University of Michigan375 enrolled16 locationsNCT04571658
Recruiting
Phase 2Phase 3

Evaluation of Efficacy, Safety, and Tolerability of Povetacicept in Participants With Primary Membranous Nephropathy (pMN)

Primary Membranous Nephropathy
Vertex Pharmaceuticals Incorporated176 enrolled98 locationsNCT07204275
Recruiting
Phase 1Phase 2

A Phase 1/2 Study of NKX019 in Subjects With Autoimmune Disease (Ntrust-1)

Lupus NephritisPrimary Membranous Nephropathy
Nkarta, Inc.120 enrolled19 locationsNCT06557265
Recruiting

RESistance of IgA Nephropathy to Conventional and Newly-approved Therapies: an Observational, Real-life Study (RESIGAN)

IgA Nephropathy (IgAN)
Assistance Publique - Hôpitaux de Paris800 enrolled1 locationNCT06926244
Recruiting
Phase 2

Therapeutic Effect of Hydroxychloroquine on Immunoglobulin A (IgA) Nephropathy Course QUIgAN Study

IgA Nephropathy
Centre Hospitalier Universitaire de Saint Etienne334 enrolled7 locationsNCT06350630
Recruiting
Phase 1

Study of BHV-1400 in IgA Nephropathy

IgA Nephropathy
Biohaven Therapeutics Ltd.20 enrolled15 locationsNCT07054684
Recruiting
Phase 2

A Study of the Safety and Activity of Sparsentan for the Treatment of Patients With Immunoglobulin A Nephropathy

Kidney DiseasesImmune System DiseasesAutoimmune Diseases+3 more
University of Leicester24 enrolled6 locationsNCT04663204
Recruiting
Phase 3

Study to Assess the Efficacy, Pharmacokinetics, Safety and Tolerability of Iptacopan in Pediatric Patients With Primary IgAN

Primary Immunoglobulin A Nephropathy (IgAN)
Novartis Pharmaceuticals31 enrolled17 locationsNCT06994845
Recruiting
Phase 2

A Study to Evaluate the Long-Term Safety and Efficacy of HSK39297 Tablets in Primary IgA Nephropathy

IgA Nephropathy (IgAN)
Haisco Pharmaceutical Group Co., Ltd.73 enrolled2 locationsNCT07616700
Recruiting
Phase 3

Phase Ⅲ Study of Efficacy and Safety of HSK39297 Tablet in Treatment of Patients With Primary IgAN

IgA Nephropathy (IgAN)
Haisco Pharmaceutical Group Co., Ltd.370 enrolled9 locationsNCT07390123
Recruiting
Phase 2

A Study of JADE101 in Participants With Immunoglobulin A Nephropathy

IgA Nephropathy
Jade Biosciences, Inc.30 enrolled7 locationsNCT07541287
Recruiting
Not Applicable

Daily Hand-Held Vibration Therapy

CancerChemotherapeutic ToxicityNeuropathy+1 more
Indiana University16 enrolled3 locationsNCT04207437
Recruiting
Phase 2

A Study to Assess the Effects of Zigakibart on IgA Nephropathy.

Immunoglobulin A Nephropathy (IgAN)
Novartis Pharmaceuticals32 enrolled9 locationsNCT07146906